Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Chin Med J (Engl). 2023 Jul 5;136(13):1532-1538. doi: 10.1097/CM9.0000000000002457.
Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death. Therefore, we aimed to investigate the risk of second primary lung cancer (SPLC) in patients with thyroid cancer.
We searched the PubMed, Web of Science, Embase, and Scopus databases up to November 24, 2021, for relevant research and merged the standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs) to evaluate the risk of developing SPLC in patients with thyroid cancer.
Fourteen studies involving 1,480,816 cases were included in our meta-analysis. The pooled result demonstrated that thyroid cancer patients may have a higher risk of SPLC than the general population (SIR = 1.21, 95% CI: 1.07-1.36, P < 0.01, I2 = 81%, P < 0.01). Subgroup analysis stratified by sex indicated that female patients may have a markedly higher risk of SPLC than male patients (SIR = 1.65, 95% CI: 1.40-1.94, P < 0.01, I2 = 75%, P < 0.01).
Thyroid cancer patients are more likely to develop SPLC than the general population, especially women. However, other risk factors must be investigated, and more prospective studies are needed to confirm our results.
International Prospective Register of Systematic Reviews: No. CRD42021285399.
先前的研究表明，患有第二种原发性恶性肿瘤的癌症幸存者人数正在增加，尤其是甲状腺癌患者，而肺癌仍然是癌症死亡的主要原因。因此，我们旨在调查甲状腺癌患者发生第二种原发性肺癌（SPLC）的风险。
我们检索了 PubMed、Web of Science、Embase 和 Scopus 数据库，截至 2021 年 11 月 24 日，以获取相关研究，并合并标准化发病比（SIRs）和 95%置信区间（95%CI），以评估甲状腺癌患者发生 SPLC 的风险。
我们的荟萃分析纳入了 14 项研究，共涉及 1480816 例病例。汇总结果表明，甲状腺癌患者发生 SPLC 的风险可能高于普通人群（SIR=1.21，95%CI：1.07-1.36，P<0.01，I2=81%，P<0.01）。按性别分层的亚组分析表明，女性患者发生 SPLC 的风险可能明显高于男性患者（SIR=1.65，95%CI：1.40-1.94，P<0.01，I2=75%，P<0.01）。
与普通人群相比，甲状腺癌患者更有可能发生 SPLC，尤其是女性。然而，还必须调查其他危险因素，并且需要更多的前瞻性研究来证实我们的结果。
国际前瞻性系统评价注册库：No. CRD42021285399。
Zotero 插件
